TORONTO--(BUSINESS WIRE)--Merz Pharma Canada, Ltd., affiliate of the global Merz Pharma Group, today announced that it has signed an agreement with Ulthera, Inc. which grants Merz exclusive rights for the marketing and distribution of the full line of Ulthera products in Canada, including their proprietary ultrasound platform device the Ulthera® System.
This agreement establishes Merz Pharma Canada as the first Merz affiliate to offer a full portfolio of aesthetic treatment options that includes the energy-based Ultherapy® treatment, a complete line of aesthetic injectables and the topical skincare products of NEOCUTIS.
“We are proud to be able to provide patients and physicians in Canada with innovative treatment options along the full continuum of aesthetic care,” said Bill Humphries, President and Chief Executive Officer of Merz North America. “As we work to expand Merz’s leadership in aesthetics, we look forward to bringing Ulthera’s proprietary skin-lifting and tightening system to new patients and physicians around the world via our global network of Merz affiliates.”
A global leader in non-surgical lifting and tightening treatments, Ulthera, Inc. was acquired by the Merz Pharma Group in July 2014. Ulthera focuses on developing and commercializing technologies for aesthetic and medical applications using its therapeutic ultrasound platform technology.
“We are pleased to assume responsibility for the marketing of Ulthera products in Canada,” said Bob Bennett, President and General Manager of Merz Pharma Canada, Ltd. “This collaboration with Ulthera strengthens our combined presence in the Canadian aesthetics space and allows us to provide our physician partners with a broader range of products to satisfy the aesthetic desires of their patients.”
The Ulthera® System was first granted clearance for lifting and tightening lax skin by Health Canada in 2009 and is currently cleared to treat the face, neck and chest. Ulthera products were previously distributed in Canada by Clarion Medical Technologies.
About Merz North America
Merz North America is a specialty healthcare company that develops and commercializes innovative, high-quality treatment solutions in aesthetics, dermatology and neurosciences in the U.S. and Canada. Our ambition is to become the most admired, trusted and innovative aesthetics and neurotoxin company. By developing products that improve patients’ health and help them to live better, feel better and look better, we will continue to make significant contributions to the well-being of individuals around the world.
For more information about Merz Pharma Canada, Ltd. or their products, please visit www.merzcanada.com. For information regarding Merz products and operations in the United States, please visit www.merzusa.com.
Ulthera, Inc. is a global, high-growth medical device company pioneering aesthetic and medical applications using its therapeutic ultrasound platform technology. The Ulthera® System is the first and only energy-based device to receive FDA clearance for a non-invasive aesthetic lift indication. It is used in a face and neck procedure known as Ultherapy®, which is cleared to lift skin on the brow, neck and under the chin and to improve lines and wrinkles of the décolleté. Founded in the US in 2004, Ulthera was acquired by Merz Pharma Group in July 2014. For more information, please visit www.Ulthera.com.